Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...

31 study showed that giving Imfinzi (durvalumab) as adjuvant therapy for stage IB-IIIA non-small cell lung cancer (NSCLC) was no better than placebo at extending disease-free survival (DFS).

The trial is targeting patients with Stage II, IIIA or IIIB (N2 ... overall survival rates for patients with non-small cell ...

Health Canada has approved MSD's anti-programmed cell death protein 1 (PD-1) therapy Keytruda for treating adults with ...

It's never too late to stop smoking. About 90% of lung cancers are attributable to smoking, and smokers have a 20-fold higher lifetime risk for developing lung cancer than do nonsmokers.

Researchers found that, in patients with stage III NSCLC, treatment with cCRT and an ICI was safe, but treatment with cCRT and 2 ICIs led to “excessive mortality.” ...

In 2013, it was designated a National Clinical Research Centre for Cancer by China’s Ministry ... therapy to chemotherapy for stage IIIA non-small cell lung cancer (NSCLC) patients with ...

MSD and partner Moderna have started a late-stage trial of their personalised cancer vaccine V940 as a combination with MSD’s PD-1 inhibitor Keytruda for patients with non-small cell lung cancer ...

1,3 Tagrisso (osimertinib) received a positive recommendation from NICE for NHS use as an adjuvant treatment option after complete tumour resection in adult patients with stage IB-IIIA non-small cell ...